ShijingLuo Ph.D. (Nora)


New York + 1.212.326.3872

Nora Luo focuses on patent prosecution and strategic intellectual property counseling in the biotechnology and pharmaceutical industries. Her practice includes preparation and prosecution of U.S. and international patent applications, patent portfolio management, due diligence evaluations, freedom-to-operate analyses, patentability evaluations, and inter partes review proceedings.

Nora has worked with established companies, start-ups, and research institutions. She has experience with a wide range of technologies, including immunotherapy (for example, antibodies, antibody drug conjugates, vaccines, cell-based therapies, CAR-T cell technology, immune checkpoint modulators), gene therapy, CRISPR technology, mRNA delivery, mRNA-based therapy, lipid nanoparticles, viral vector-based gene delivery system (for example, AAV [adeno-associated virus]), antibody engineering, RNA splicing, cancer therapeutics, virology, stem cells, neurological disorder therapeutics, high-throughput screening, genomics, diagnostic assays, anti-aging therapeutics, and small molecule pharmaceuticals.

Nora holds a Ph.D. in molecular biology from Princeton University. While at Princeton, she was awarded the American Society for Cell Biology Norton B. Gilula Award and was the recipient of the National Institute of Health Fellowship. Prior to joining Jones Day, Nora was a Damon Runyon Cancer Research fellow at The Rockefeller University. Her scientific work has been published in a number of peer-reviewed journals, including Cell and Science, and was featured in The New York Times and Nature.


  • Turnstone Biologics develops patent portfolios for its oncolytic virus clinical candidateJones Day is representing Turnstone Biologics Corp. in the development of patent portfolios covering its oncolytic virus programs, including its current clinical candidate.
  • Celgene develops patent portfolio for anti-CD47 therapeutic antibodiesJones Day represented Celgene Corporation in the development of a portfolio of patents directed to anti-CD47 therapeutic antibodies.
  • Celgene develops worldwide patent portfolios covering CAR-T and other cellular therapeuticsJones Day is advising Celgene Corporation in the strategic development of worldwide patent portfolios covering CAR-T and other cellular therapeutics.
  • Celldex Therapeutics develops worldwide patent portfolios for anti-tyrosine kinase receptor therapeutic antibodiesJones Day is representing Celldex Therapeutics, Inc. in connection with the development and prosecution of global portfolios related to the company's lead clinical and pre-clinical anti-tyrosine kinase receptor therapeutic antibodies.
  • Biogen MA builds patent portfolio relating to Tecfidera®Jones Day represents Biogen MA Inc. in patent prosecution and portfolio development relating to Tecfidera®.